Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7748/paed2002.04.14.3.22.c791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical comprehensive evaluation of Jiangzhi Tongluo Soft Capsules for treating hyperlipidemia (syndrome of blood stasis and Qi stagnation)].
Zhongguo Zhong Yao Za Zhi
October 2024
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
This study provides a systematic review of existing evidence concerning the efficacy of Jiangzhi Tongluo Soft Capsules(JTSC) in treating hyperlipidemia(syndrome of blood stasis and Qi stagnation), following the Guidelines for clinical evidence and value assessment of drugs. The qualitative and quantitative methods were integrated, including questionnaire surveys, evidence-based medicine, and pharmacoeconomic evaluation. Multi-criteria decision analysis(MCDA) model was used for comprehensive assessment of the clinical evidence and value of JTSC for hyperlipidemia in "6+1" dimensions: safety, effectiveness, cost-effectiveness, innovation, suitability, accessibility, and traditional Chinese medicine(TCM) characteristics.
View Article and Find Full Text PDF[Expert consensus on clinical application of Dieda Qili Tablets in treatment of acute soft tissue injury].
Zhongguo Zhong Yao Za Zhi
September 2024
Wangjing Hospital of China Academy of Chinese Medical Sciences Beijing 100102, China Beijing Key Laboratory of Orthopaedic Technology of Traditional Chinese Medicine Beijing 100102, China.
Dieda Qili Tablets are protected traditional Chinese medicine(TCM) variety and type B medicine included in medical insurance in China, which is widely used in the treatment of acute soft tissue injury in clinical practice and has been recommended by many books. However, there is no evidence-based guideline or consensus to guide the clinical application of Dieda Qili Tablets. With the support of China Association of Chinese Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences led the 21 Chinese units to follow the guiding ideology of "evidence as the key, consensus as the supplement, and experience as the reference" to compile this consensus.
View Article and Find Full Text PDFComparative efficacy and safety of Chinese patent medicines for primary insomnia: A systematic review and network meta-analysis of 109 randomized trials.
J Ethnopharmacol
December 2024
Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China; Centre for Evidence-Based Social Science/Center for Health Technology Assessment, School of Public Health, Lanzhou University, 730000, Lanzhou, China; Gansu Key Laboratory of Evidence-Based Medicine, Lanzhou University, 730000, Lanzhou, China. Electronic address:
Ethnopharmacological Relevance: Chinese patent medicine (CPM) is formulated using Chinese herbal medicines as raw materials according to prescribed methods and preparation processes. It is one of the most commonly used complementary and alternative therapies for insomnia in China. Dozens of CPMs have been applied in clinical settings to treat primary insomnia, and ample evidence has proven the efficacy and safety of various CPMs.
View Article and Find Full Text PDFTreatment for women with postpartum iron deficiency anaemia.
Cochrane Database Syst Rev
December 2024
Cochrane Denmark and Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense, Denmark.
Rationale: Postpartum iron deficiency anaemia is caused by antenatal iron deficiency or excessive blood loss at delivery and might affect up to 50% of labouring women in low- and middle-income countries. Effective and safe treatment during early motherhood is important for maternal well-being and newborn care. Treatment options include oral iron supplementation, intravenous iron, erythropoietin, and red blood cell transfusion.
View Article and Find Full Text PDFAt-Home Self-Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open-Label Feasibility Trial.
Clin Pharmacol Drug Dev
January 2025
Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
Article Synopsis
- A Phase 1, open-label pharmacokinetic trial was conducted to compare the timing accuracy of participant-collected versus staff-collected data for the drug centanafadine.
- Healthy adults aged 18-55 received the drug and had their pharmacokinetic samples and safety assessments collected at different visits, with incremental levels of participant involvement over the visits.
- The study found that at least 75% of participants successfully collected blood microsamples on time, and there were no treatment-related adverse events, supporting the feasibility of at-home data collection for pharmacokinetics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!